

# Kiribati

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.03 (0.021–0.04)	27 (19–36)
Mortality (HIV+TB only)	<0.01 (<0.01–<0.01)	0.47 (0.18–0.9)
Incidence (includes HIV+TB)	0.62 (0.48–0.78)	551 (425–695)
Incidence (HIV+TB only)	<0.01 (<0.01–<0.01)	2.3 (1.7–3)
Incidence (MDR/RR-TB)**	0.041 (0.025–0.056)	36 (22–50)

Estimated TB incidence by age and sex (thousands)*, 2015			
	0-14 years	> 14 years	Total
Females	0.029 (0.013–0.045)	0.26 (0.17–0.34)	0.28 (0.19–0.38)
Males	0.034 (0.021–0.046)	0.3 (0.23–0.38)	0.34 (0.25–0.42)
Total	0.062 (0.043–0.082)	0.56 (0.47–0.64)	0.62 (0.48–0.78)

TB case notifications, 2015	
Total cases notified	516
Total new and relapse	496
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	42%
- % pulmonary	86%
- % bacteriologically confirmed among pulmonary	68%

Universal health coverage and social protection	
TB treatment coverage (notified/estimated incidence), 2015	80% (64–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.05 (0.03–0.07)

TB/HIV care in new and relapse TB patients, 2015		
	Number	(%)
Patients with known HIV-status who are HIV-positive	1	<1%
- on antiretroviral therapy	1	100%

Drug-resistant TB care, 2015			
	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			29 (20–38)
Estimated % of TB cases with MDR/RR-TB	5.2% (3.1–7.3)	28% (25–30)	
% notified tested for rifampicin resistance	0%	0%	0
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size		
	Success	Cohort
New and relapse cases registered in 2014	87%	415
Previously treated cases, excluding relapse, registered in 2014	88%	17
HIV-positive TB cases, all types, registered in 2014	0%	1
MDR/RR-TB cases started on second-line treatment in 2013		0
XDR-TB cases started on second-line treatment in 2013		0

TB preventive treatment, 2015	
% of HIV-positive people (newly enrolled in care) on preventive treatment	33%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

TB financing, 2016	
National TB budget (US\$ millions)	<1
Funding source: 0% domestic, 100% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2015



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

